Abstract: The present invention is directed to methods of treating diseases and disorders of the skin (e.g., acne) with heat-enabled photodynamic therapy (HEPT). Methods of treating acne, non-melanoma skin cancer (NMSC), actinic keratosis (AK) or disseminated superficial actinic porokeratosis (DSAP) using red light photodynamic therapy on heat-treated skin.

Abstract: The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.

Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Abstract: The invention provides a drug delivery system for a combination of therapeutic agents. The system includes a water soluble biodegradable ABA-type triblock copolymer that possesses thermosensitive gelation properties. The system can form a stable thermogel that includes a combination of therapeutic agents including, for example, rapamycin, paclitaxel, and 17-AAG. After administration to a subject, the drugs are released at a controlled rate from the thermogel, which biodegrades into non-toxic components. The polymer system can also function to increase the solubility and stability of drugs in the composition.

Abstract: To provide a protein preparation which enables reduction of aggregation and a stable long-time preservation, in a protein preparation having a high concentration or a protein preparation susceptible to aggregation. The protein preparation is a gel preparation which is thixotropic and in which an included protein is protected from a physical or chemical stress, is inhibited from aggregation, and thereby stably exists.

Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.

Abstract: Disclosed are an intermediate drug having synergistic anticancer activity and a polyethylene glycol-coupled synergistic anticancer drug, and a method preparing therefor and use thereof. The intermediate drug has the general structural formula of (I), and the polyethylene glycol-coupled synergistic anticancer drug has the general structural formula of (II). The drugs achieve the combined medication of various anticancer drugs and avoid the toxic reaction caused by the interaction among the drugs or by the pharmacokinetics of the drugs when taking various anticancer drugs, facilitate overcoming the multidrug resistance of cancers, have a synergistic effect, and can be used for preparing anticancer medicaments and for treating cancers.

Abstract: The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to regenerating muscle tissue, comprising at least a therapeutic drug or gene, associated to a syncytin protein, and its use in the prevention and/or treatment of muscle injuries or diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein.

Abstract: The present invention provides multi-armed high MW polymers containing hydrophilic groups conjugated to Factor VIII, and methods of preparing such polymers.

Abstract: The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.

Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Abstract: The present disclosure relates to the use of silica-forming peptides (SFPs) Volp1 and Salp1 for protein fusion tags for protein purification, silica formation and self-encapsulation, and controlled release of biomolecules. After preparing a fusion protein containing the Volp1 or Salp1 peptide at the C-terminal of the protein, the adsorption conditions for silica (SiO2) surface were optimized. As a result, a high-purity fusion protein could be purified without an additional tag for purification. The fusion protein containing the silica-forming peptide was self-encapsulated and stably immobilized in the silica matrix through reaction with a silica precursor. The Volp1 and Salp1 peptides showed stronger adsorption ability for silica than the previously known R5 peptide. Using these characteristics, a silica complex wherein two proteins are encapsulated was prepared by mixing the R5 fusion protein with the Volp1 or Salp1 fusion protein.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.

Abstract: Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer. Methods of use of the therapeutic compositions are also disclosed.

Abstract: The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.

Abstract: Provided herein are recombinant adeno-associated virus (rAAV) vectors comprising nucleic acid encoding N-acetyl-glucosamine-1-phosphate transferase, alpha and beta subunits (GNPTAB) and at least one AAV inverted terminal repeat (ITR). In some embodiments, the rAAV vectors may be included in a rAAV particle, which may be contained in pharmaceutical compositions and kits. These vectors, particles, compositions, and kits may find use, inter alia, in methods and uses related to treating mucolipidosis type II (ML II) or mucolipidosis type III (ML III) in a mammal, or related to increasing body size, bone mineral content, and/or bone mineral density in a mammal with mucolipidosis type II (ML II) or mucolipidosis type III (ML III).

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

Abstract: The invention relates to methods for the treatment and/or prevention of pain, excessive neuronal activity, or epilepsy, and to gene therapy vectors. In particular, the method comprises the overexpression of a CASPR2 polypeptide in sensory neurons of the individual and the gene therapy vector comprises a polynucleotide sequence that encodes a CASPR2 polypeptide or a variant thereof.

Abstract: The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IX? reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.

Abstract: This disclosure relates to the field of fluorescent dyes, and in particular, compositions and methods for increasing fluorescent signals and the reduction of fluorescent quenching.

Abstract: The problem to be solved is to provide an anti-human MUC1 antibody Fab fragment that is expected to be useful in the diagnosis and/or treatment of a cancer, particularly, the diagnosis and/or treatment of breast cancer or bladder cancer, and a diagnosis approach and/or a treatment approach using a conjugate comprising the Fab fragment. The solution is an anti-human MUC1 antibody Fab fragment comprising a heavy chain fragment comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 8 or 10, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 12, and a conjugate comprising the Fab fragment.

Abstract: The present invention provides a 19F-MR/fluorescence multi-mode molecular imaging and drug loading diagnosis-treatment integrated nanoprobe, and a preparation method and an application. The nano-probe is a nanoparticle formed by coating a mixture of a surfactant containing a molecular targeting treatment drug and a fluorescent dye with a Perfluorocarbon (PFC) carrier; and by uniformly dispersing a mixed solution into water and glycerol, processing ultrasonically, removing a component which is not effectively coated, and purifying, the drug-loading nanoparticle capable of being used for 19 F-MR imaging may be prepared.

Abstract: Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.

Abstract: Methods of and systems for making a hyperpolarized fluid are provided, which include exposing a fluid and parahydrogen to a catalyst. The hyperpolarized fluid can be introduced to a subject. The hyperpolarized fluid can be included in methods of imaging a subject. Also provided are methods that use the hyperpolarized fluids for detecting protein ligand interactions and for enhancing the NMR signals of biopolymers having chemically exchangeable protons.

Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.

Abstract: A standalone UV-C sanitizing apparatus and method is provided that is operable to sanitize and disinfect a user's hands or protective gloves. The apparatus includes a housing with light emitting diodes (LEDs) positioned to emit ultraviolet (UV-C) light connected to a circuit board which are individually connected to a power source. The apparatus is configured so that when the user positions the hands or gloves under the housing, the UV-C light is emitted for a predetermined period of time based on the distance to the hands and the power output of the LEDs. The UV-C light is emitted at a wavelength suitable to kill, destroy, or reduce growth of microorganisms/germs. The housing can be configured with a sensor to detect motion under the housing and include a limiter hand guard.

Abstract: A method for pressurizing a sterilization chamber of a steam sterilizer with a controlled rate of pressure change. Pressure is increased in the sterilization chamber by opening a steam-to-chamber valve for a pulse duration during each of a plurality of time PERIODS needed to reach a target pressure value. During each time PERIOD, the steam-to-chamber valve is moved to an open state for the duration of the pulse. An error value indicative of the difference between a Theoretical Pressure and a Measured Pressure is determined at the end of each PERIOD. This error value is used to determine the duration of the pulse for the subsequent PERIOD, thereby maintaining a desired rate of pressure change in the sterilization chamber.

Abstract: According to an aspect of the invention, an indwelling catheter is provided which comprises a catheter shaft. The catheter either comprises a light source or is adapted to receive light from a light source, and is configured such that light is transmitted from the light source into the catheter shaft. Moreover, the catheter shaft is formed of a polymeric material that transmits a quantity of light from the light source that is effective to inactivate microorganisms on a surface of the catheter shaft upon activation of the light source. For example, the light may inactivate the microorganisms directly or in conjunction with a photosensitizer. According to another aspect of the invention, a sterilization method is provided, which comprises activating the light source while the catheter is inserted in a subject.

Abstract: A disinfecting system includes a housing. An ultraviolet light (UV) source is secured to the housing and configured to emit UV light for disinfection of a target. A processor is secured to the housing in communication with the UV light source. The processor is configured to activate the UV light source for a selected amount of time suitable for disinfection of the target.

Abstract: A system may automatically conduct hygiene cycles for a confined space such an interior space of a box suitable for storing and/or carrying packaged food. The system may include a hygiene device that can be attached to the box to conduct the hygiene cycles and a user interface device that can wirelessly communicate with the hygiene device to control the conduction of the hygiene cycles. The system may also automatically collect information related to the hygiene cycles using the hygiene device and transmit the collected information to a network directly or through the user interface device.

Abstract: A dispenser includes a housing having a power source. A piezoelectric cartridge is installable within the housing and includes a cartridge body, a piezoelectric discharge nozzle supported by the cartridge body and a micro-perforated vibratory plate. The discharge nozzle is powered by the dispenser when the piezoelectric cartridge is installed within the housing of the dispenser. A fragrance bottle is supported by the cartridge body. The cartridge body further has a liquid fragrance path from the bottle to the piezoelectric nozzle. The path includes a channel with a wick. The wick is in contact with the vibratory plate of the piezoelectric discharge nozzle.

Abstract: Disclosed herein are a vascular graft and a method for sealing a vascular graft. The method generally includes applying a hydrogel sealant to the vascular graft thereby sealing the graft, wherein the hydrogel sealant is prepared from material selected from the group consisting of plant sourced material, synthetic material, or a combination thereof. In some embodiments, the hydrogel sealant may be prepared from albumin and a crosslinking agent or from poly(ethylene)oxide and a poly(amine).

Abstract: The invention is directed to a biodegradable tissue-adhesive device for sealing tissue, said device comprising a tissue-adhesive layer which comprises a blend of a tissue-reactive polymer and a biodegradable carrier polyurethane according to the formula of ?A-B-C-B?n, wherein A denotes a polyol, B denotes a diisocyanate moiety, C denotes a diol component and n denotes the number of recurring units, and wherein the B-C-B segment is bioresorbable.

Abstract: The invention provides a novel, versatile degradable hydrogel composition, and methods thereof, with precisely tunable stiffness, plasticity (e.g., degree of covalent vs. physical crosslinks) and predictive disintegration rates degradation, allowing controlled disintegration and release of therapeutic cells or pharmaceuticals and/or in vitro 3D cell expansion.

Abstract: The invention provides bioresorbable nerve guidance conduits made from polymer blends which include polyhydroxyalkanoates (PHAs). In particular, the invention provides nerve guidance conduits having a body which comprises a polymer blend comprising: (a) from 60 to 98 wt. % of a first component which is a PHA copolymer comprising two or more different medium chain length hydroxyalkanoate monomer units; and (b) from 2 to 40 wt. % of a second component which is either a PHA homopolymer containing a short chain length hydroxyalkanoate monomer unit, or a polylactide (PLA). The invention further relates to polymer blends comprising (a) and (b).

Abstract: The present disclosure relates to methods and compositions comprising dissociated buccal mucosa tissue that are useful for treating a wound. Kits for preparing the liquid suspension of dissociated buccal mucosa tissue and treating the wound are also disclosed.

Abstract: The present invention provides a system for artificially inducing and regulating “tissue interactions” among multiple tissues. A construct for transplantation into a living body, which comprises a structure and a cell mass linked to each other, the structure being an object having a three-dimensional structure and capable of mimicking or resembling a structure and/or a function of the living body.

Abstract: Methods and compositions for the biological repair of cartilage using a hybrid construct combining both an inert structure and living core are described. The inert structure is intended to act not only as a delivery system to feed and grow a living core component, but also as an inducer of cell differentiation. The inert structure comprises concentric internal and external and inflatable/expandable balloon-like bio-polymers. The living core comprises the cell-matrix construct comprised of HDFs, for example, seeded in a scaffold. The method comprises surgically removing a damaged cartilage from a patient and inserting the hybrid construct into the cavity generated after the foregoing surgical intervention. The balloons of the inert structure are successively inflated within the target area, such as a joint, for example. Also disclosed herein are methods for growing and differentiating human fibroblasts into chondrocyte-like cells via mechanical strain.

Abstract: The invention involves a kind of electrified composite membrane with extracellular matrix electrical topology characteristics and its preparation method, which resolves the technical problems of poor matching of electric characteristics and natural extracellular matrix characteristics in the existing materials and limited restoration effect of materials. The invention provides a kind of electrified composite membrane with extracellular matrix electrical topology characteristics mainly composed of ferroelectric polymer matrix and piezoelectric active fiber fillings. By regulating the draw ratio, content and of piezoelectric active fiber and thickness of composite film, the invention can realized the flexibility of film material and electrical topological features of bionic extracellular matrix, with proper tissue adhesion and good electric adaptability and high clinical operability.

Abstract: A load-bearing bone fixation composite includes a polymer matrix, a plurality of polymer fibers aligned along a common axis and disposed in the polymer matrix, wherein the polymer matrix binds the surface of the polymer fibers, and a plurality of high aspect ratio nanorods coating at least a portion of each of the polymer fibers, wherein the long axis of at least a portion of the nanorods is aligned with the common axis, and wherein the high aspect nanorods have an aspect ratio of 10 or greater. Further included is a bone fixation device including the foregoing composite. A method of bone fixation comprises affixing the foregoing composite to a site of a load-bearing bone fracture, or maxillofacial bone fracture. Also included are methods of making the composites.

Abstract: The present invention relates to the unexpected discovery of 3D printed biomimetics of growth plate cartilage and methods using the same for the treatment of growth plate defects. In certain embodiments, the methods prevent the growth of bony bars at the site of growth plate injury, thereby preventing growth arrest and/or deformity.

Abstract: Articles and methods involving soft tissue repair implants comprising 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or their conjugate acids are generally provided. The 2-hydroxybutyrate, 3-hydroxybutyrate, 4-hydroxybutyrate, and/or the conjugate acid(s) of 2-hydroxybutyrate, 3-hydroxybutyrate, and 4-hydroxybutyrate may be provided in a therapeutically-effective amount for reducing or preventing microbial infection.

Abstract: Provided is a lyophilized implant configured to fit at or near a bone defect to promote bone growth, the lyophilized implant containing a biodegradable polymer in an amount of about 0.1 wt. % to about 20 wt. % of the implant, mineral particles in an amount from about 0.1 wt. % to about 75 wt. % of the implant, and an oxysterol in an amount of about 5 wt. % to about 90 wt. % of the implant. Methods of making and using the implant are further provided.

Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

Abstract: The present invention relates to the use of a copolymer containing polyether blocks and polyamide blocks for manufacturing an inflatable catheter element, such as a catheter balloon, with improved bursting strength, in which said copolymer has the following characteristics: a number-average molecular mass of the PE blocks greater than 500 g/mol, and a number-average molecular mass of the PA blocks greater than 10,000 g/mol.

Abstract: An apparatus and method are disclosed for a biofunctional molecular imprint medical device configured to remain in permanent or temporary contact with a body comprising a supportive structure, a surface material that receives and retains a molecular imprint and that is positioned to contact a body tissue or other substance during use, a molecular imprint of a bioactive molecule wherein an imprinted cavity is of a bioactive molecule that catalyzes the promotion or suppression biological processes and at least one of a semiconductor, a nanoparticle quantum dot, a nano-island, and a quantum wire, wherein the nanoparticle quantum dot, nano-island, or quantum wire produces an electron wave function configuration that dynamically reconfigures the electron charge distribution within the molecular imprint, enabling tuning of the imprinted cavity.

Abstract: In some embodiments, a wound monitoring and/or therapy apparatus can include a wound dressing configured to be positioned over a wound. The wound dressing can support one or more sensors. The one or more sensors can include an optical sensor array cluster, which can include an optical sensor and single light source. In some embodiments, the wound dressing can include a substantially stretchable wound contact layer that includes a wound facing side and a non-wound facing side opposite the wound facing side, the wound facing side configured to be positioned in contact with a wound. The non-wound facing side of the wound contact layer can support a plurality of electronic components and a plurality of electronic connections that connect at least some of the plurality of the electronic components. The electronic components can include one or more sensors configured to obtain measurements of the wound or the periwound, or both.